Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma, Kaposi 3Myeloproliferative Disorders 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Acquired Immunodeficiency Syndrome 2Plasmablastic Lymphoma 1Optic Nerve Glioma 1Neurofibromatosis 1 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Lymphoma, Primary Effusion 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Epstein-Barr Virus Infections 1Central Nervous System Neoplasms 1Burkitt Lymphoma 1

Interventions

Rituximab 3Vincristine 2Prednisone 2Matrix-M 2Etoposide 2Doxorubicin 2Cyclophosphamide 2threonic acid 1pomalidomide 1Zidovudine 1Tomography, X-Ray Computed 1Nivolumab 1Methotrexate 1Magnesium Sulfate 1Leucovorin 1Interferons 1Echocardiography 1EPOCH protocol 1Caves 1Acyclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Epstein-Barr Virus Infections × pomalidomide × Clear all
NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡